HER2CLIMB Guide

What HER2CLIMB is

HER2CLIMB is the name of the pivotal tucatinib trial and the regimen that grew out of it: tucatinib + trastuzumab + capecitabine for previously treated HER2-positive metastatic breast cancer.

It emerged in the late 2010s as a key study in patients who had already received earlier HER2-directed therapy.

What the main findings showed

So far, HER2CLIMB is best known for showing that adding tucatinib to trastuzumab and capecitabine improved outcomes compared with trastuzumab and capecitabine alone.

The most important findings were:

• improved progression-free survival

• improved overall survival

• meaningful benefit in patients with brain metastases

That is why the regimen became an important later-line option in HER2-positive metastatic breast cancer, especially when CNS disease is part of the picture.

This page brings together the main HER2CLIMB-related pages across the site.

Use it as the starting point if you are trying to understand:

• why the regimen may stop working

• what resistance testing may or may not show

• whether tucatinib exposure could be altered

• whether supplements may affect CYP3A4-related drug handlingStart here

HER2CLIMB Resistance Mechanisms

Read this first for the main biological routes by which tumours may bypass tucatinib, trastuzumab, and capecitabine.

Liquid Biopsy for HER2-Positive Resistance

Use this next if you want to understand what ctDNA can detect, what it often misses, and how to interpret a negative result carefully.

Tucatinib Clearance, Genetics, and Enzyme Inducers

Read this if the question is whether genetic variation, CYP3A4, CYP2C8, or enzyme induction could be reducing tucatinib exposure.

Natural Compounds and CYP3A4 — HER2CLIMB Considerations

Use this for a side-by-side view of how commonly used supplements may affect CYP3A4 in the HER2CLIMB setting.

Best way to use these pages

1. Start with the resistance page.

2. Check the liquid-biopsy page if testing is being discussed.

3. Review tucatinib-clearance issues if drug exposure may be relevant.

4. Review supplement-interaction pages before adding or continuing natural compounds.

Questions this hub helps answer

• Is this progression more likely to reflect bypass signalling, phenotype change, or exposure issues?

• What can a liquid biopsy actually show in this setting?

• Could tucatinib be clearing too quickly in some patients?

• Are any supplements likely to matter enough to change drug exposure?

Likely next pages to come

This HER2CLIMB section will expand with pages on:

• side effects on HER2CLIMB

• CNS progression and brain-metastasis relevance

• questions to ask after progression

• options after tucatinib-based treatment

Would you like to ask Abbey about the information shared on this page? Would you like to contribute your experience, research or ideas to this page? Perhaps you want to point out something that needs changing?

Feedback Form